Suntinorexton (INNTooltip International Nonproprietary Name; developmental code name TAK-861) is an experimental orexin receptor agonist.

[1][2] It acts as a selective agonist of the orexin OX2 receptor and was described in 2019 in a patent by Takeda Pharmaceutical Company.

[3] Suntinorexton superseded firazorexton (TAK-994) as a clinical drug candidate following evidence of hepatoxicity in humans.

[1] The drug has reached phase 3 clinical trials as of 2024.

[1] This drug article relating to the nervous system is a stub.